Protection from septic shock by neutralization of macrophage migration inhibitory factor

Nature Medicine

Volumn 6, Issue 2, 2000, Pages 164-170

  Calandra, Thierry ^a   Echtenacher, Bernd ^b   Le Roy, Didier ^a   Pugin, Jéròme ^c   Metz, Christine N ^d   Hültner, Lothar ^d   Heumann, Didier ^a   Männel, Daniela ^b   Bucala, Richard ^e   Glauser, Michel P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d PICOWER INST FOR MEDICAL RESEARCH   (United States)

^e Gesundheit Inst Experimentelle H   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 ANTIBODY; MACROPHAGE MIGRATION INHIBITION FACTOR; MACROPHAGE MIGRATION INHIBITION FACTOR ANTIBODY; PROTEIN ANTIBODY; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BACTERIAL PERITONITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; FEMALE; HUMAN; IMMUNOTHERAPY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PERITONEUM EXUDATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SEPTIC SHOCK;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BACTERIAL INFECTIONS; FEMALE; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICE; MIDDLE AGED; PERITONITIS; SHOCK, SEPTIC;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 0001611329     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/72262     Document Type: Article

References (36)

1. Glauser, M. P., Zanetti, C., Baumgartner, J. D. & Cohen, J. Septic shock: pathogenesis. Lancet 338, 732-736 (1991).
2. Abraham, E. Why immunomodulatory therapies have not worked in sepsis? Intensive Care Med. 25, 556-566 (1999).
3. Bloom, B. R. & Bennett, B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153, 80-82 (1966).
4. David, J. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc.Natl.Acad.Sci.USA 56, 72-77 (1966).
5. Nathan, C. F., Remold, H. C. & David, J. R. Characterization of a lymphocyte factor which alters macrophage function. J. Exp. Med. 137, 275-288 (1973).
6. Nathan, C. F., Karnovsky, M. L. & David, J. R. Alterations of macrophage functions by mediators from lymphocytes. J. Exp. Med. 133, 1356-1376 (1971).
7. Bernhagen, J. et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365, 756-759 (1993).
8. Calandra, T. et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377, 68-71 (1995).
9. Calandra, T., Spiegel, L. A., Metz, C. N. & Bucala, R. Macrophage migration inhibitory factor (MIF) is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc.Natl.Afad.Sci.USA 95, 11383-11388 (1998).
10. Calandra, T., Bernhagen, J., Mitchell, R. A. & Bucala, R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179, 1895-1902 (1994).
11. Bernhagen, J. et al. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33, 14144-14155 (1994).
12. Bacher, M. et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl. Acad. Sci. USA 93, 7849-7854 (1996).
13. Mitchell, R. A., Metz, C. N., Peng, T. & Bucala, R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phopholipase A2 activation by macrophage migration inhibitory factor (MIF). J.Biol.Chem. 274, 18100-18106 (1999).
14. Lan, H.Y. et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J. Exp. Med. 185 1455-1465 (1997).
15. Mikulowska, A., Metz, C. N., Bucala, R. & Holmdahl, R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J. Immunol. 158, 5514-5517 (1997).
16. Leech, M. et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum. 41, 910-917 (1998).
17. Lan, H. Y. et al. Macrophage migration inhibitory factor expression in human renal allograft rejection. Transplantation 16, 1465-1471 (1998).
18. Donnelly, S. C. et al. Regulatory role for macrophage migration inhibitory factorin acute respiratory distress syndrome. Nat. Med. 3, 320-323 (1997).
19. Bacher, M. et al. MIF expression in experimentally-induced endotoxemia. Am. J. Pathol. 150, 235-246 (1997).
20. Bozza, M. et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189, 341-346 (1999).
21. Marschall, J. C. & Creery, D. Pre-clinical models of sepsis. Sepsis 2, 187-197 (1998).
22. Cohen, J. & Abraham, E. Microbiologic findings and correlations with serum tumor necrosis factor-α in patients with severe sepsis and septic shock. J. Infect. Dis. 180, 116-121 (1999).
23. Friedman, C., Silva, E. & Vincent, J. L. Has the mortality of septic shock changed with time? Crit. Care Med. 26, 2078-2086 (1998).
24. Zanetti, C. et al. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-α and to lipopolysaccharide. J. Immunol. 148, 1890-1897 (1992).
25. Echtenacher, B., Falk, W., Männel, D. N. & Krammer, P. H. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol. 145, 3762-3766 (1990).
26. Heumann, D. et al. Contribution of TNF/TNF receptor and of Fas ligand to toxicity in murine models of endotoxemia and bacterial peritonitis. J. Inflamm. 47, 173-179 (1999).
27. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 20, 864-874 (1992).
28. Bagby, C. J., Plessala, K. J., Wilson, L. A., Thompson, K. J. & Nelson, S. Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J. Infect. Dis. 163, 83-88 (1991).
29. Wang, H. et al. HMG-1 as a late mediator of endotoxin lethality in mice Science 285, 248-251 (1999).
30. Maurer, M. et al. The c-kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells. J. Exp. Med. 188, 2343-2348 (1991).
31. Pfeffer, K.et al. Mice deficient for the 55kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection Cell 73, 457-467 (1993).
32. Rothe, J. et al. Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364, 798-802 (1993).
33. Porat, R., Clark, B. D., Wolff, S. M. & Dinarello, C. A. Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science 254, 430-432 (1991).
34. Pasparakis, M., Alexopoulou, L., Episkopou, V. & Kollias, C. Immune and inflammatory responses in TNFα-deficient mice: a critical requirement for TNFα in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med 184, 1397-1411 (1996).
35. Baumgartner, J. D. et al. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor α and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies. J. Exp. Med. 171, 889-896 (1990).
36. Kohler, J. et al. IFN-gamma involvement in the severity of Gram-negative infections in mice. J. Immunol. 151, 916-921 (1993).